In Malaysia, the company recorded a 16% improvement in its ebitda, with revenue up 7%. Even though inpatient admissions dropped 3% supposedly due to a longer holiday season, ebitda margin was held at 26% and IHH is guiding for this metric to maintain at the mid-20s.
Amanda Tan of DBS Group Research has maintained her "buy" call on IHH Healthcare following its 1QFY2026 results, which showed "steady" core earnings growth, although somewhat blemished by unfavourable forex.
For the three months to March, IHH reported earnings of RM545 million, an increase of 5% y-o-y, in line with expectations. Revenue in the same period was up 3% y-o-y to RM6.5 billion.
